ImmunityBio (IBRX) Tests Its Valuation After UAE ANKTIVA Approval Expands Its Reach

ImmunityBio (IBRX) stock is in focus after the company secured marketing authorization in the United Arab Emirates for ANKTIVA in both BCG unresponsive non muscle invasive bladder cancer and metastatic non small cell lung cancer.

See our latest analysis for ImmunityBio.

ImmunityBio’s share price closed at US$7.64, with a 1-day share price return of 4.37% and a 7-day share price return of 6.56%. The 30-day and 90-day share price returns are both down, hinting at some cooling after a very strong year to date in which the share price return is up 278.22% and the 1-year total shareholder return is 213.11%.

If you are tracking how other healthcare names linked to advanced treatments are trading, this is a good moment to broaden your search using 43 healthcare AI stocks

After a sharp run and fresh ANKTIVA approvals expanding ImmunityBio’s reach, the stock now carries rich revenue multiples and heavy ongoing losses. Does that trade off leave more upside for new buyers, or is the easy money gone?

Most Popular Narrative: 41.2% Undervalued

On the most followed view, ImmunityBio’s fair value sits at $13, which is well above the last close at $7.64. That gap rests on some very aggressive growth and margin forecasts.

The integration of AI driven tools like askIB into R&D, manufacturing and commercial operations, along with the NANT Leonardo robotic cell manufacturing platform, is aimed at higher throughput and lower unit costs. This can support margin improvement as volumes scale and help narrow losses over time.

Read the complete narrative.

Want to see what kind of revenue ramp and margin shift would need to sit behind a $13 fair value for ImmunityBio? The narrative leans on rapid top line expansion, a sharp swing into profitability and a premium future earnings multiple to make the numbers work.

Result: Fair Value of $13 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ImmunityBio still faces key risks if ANKTIVA uptake across 33 countries is slower than analysts expect or if regulators tighten approval standards for new indications.

Find out about the key risks to this ImmunityBio narrative.

Another View: Rich Multiples For ImmunityBio

The SWS DCF model points to a fair value of $46.07 for ImmunityBio, which is very different to the $13 narrative fair value and current price of $7.64. At the same time the stock trades on a P/S ratio of 48.8x versus a US Biotechs industry average of 11.4x, a peer average of 21x and a fair ratio of 37.5x that the market could move towards. That mix of a large DCF gap and premium sales multiple raises a simple question for investors: Is this a margin of safety or a lot of future success already baked in?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

The split between an aggressive upside story and rich current multiples makes sentiment on ImmunityBio mixed. It helps to move fast and test the numbers yourself against both the risks and the potential upside that other investors are watching by reviewing the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond ImmunityBio?

If ImmunityBio has caught your attention, broaden your watchlist now and avoid missing other stocks that might suit your approach just as well.

• Spot potential value opportunities early by scanning companies that look mispriced on quality and fundamentals through the 52 high quality undervalued stocks.
• Strengthen your portfolio’s foundation by focusing on companies with robust finances using the solid balance sheet and fundamentals stocks screener (48 results).
• Unearth lesser known opportunities with strong underlying metrics by checking the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com